Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02805595 · ClinicalTrials.gov registry record · Phase 2
Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT02805595 is a Phase 2 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 21 participants.
The verdict
NCT02805595, a Phase 2 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study evaluates the effect of hypertonic saline 23.4% injection in fistulas or sinus tracts in adult patients with hidradenitis suppurativa.
Interventions
- DRUG 23.4% Hypertonic saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-08 |
| Est. Completion | 2022-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02805595
The ClinicalTrials.gov registry entry for NCT02805595 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 23.4% Hypertonic saline is the first listed.
NCT02805595 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02805595 about?
NCT02805595 is a clinical study titled "Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa". This study evaluates the effect of hypertonic saline 23.4% injection in fistulas or sinus tracts in adult patients with hidradenitis suppurativa.
What is the current status of trial NCT02805595?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2016-08. Estimated completion is 2022-11.
What interventions are being tested in trial NCT02805595?
The interventions under investigation include: 23.4% Hypertonic saline (DRUG).
Who is sponsoring clinical trial NCT02805595?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.